Skip To Main Content
Ying Choon Wu on Muck Rack

Ying Choon Wu

As seen in: AIChE Journal, British Journal of Cancer, Color Research & Application, Nature, Wiley Online Library, British Pharmacological Society, PLOS, PLOS ONE, ACS Publications, Journal of Molecular Endocrinology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying Choon

Contact Ying Choon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Characteristics and distribution of sweet spots in ultra-deep basement reservoirs in compressional tectonic settings: insights from the Northern Qaidam Basin

|
By Ying Choon Wu, Ahmed Radwan, Shuai Yin, Xiaofei Ru
| Nature Verified
Abstract Ultra-deep basement gas reservoirs typically exhibit complex lithology, strong heterogeneity, and a lack of unified classification criteria, posing significant challenges for high-quality reservoir prediction. This study focuses on the Devonian basement of the T Block in the Kunteyi Gas Field, Qaidam Basin, at depths exceeding 6000 m.
Open in Who Shared Issue with article?

Noncanonical bactericidal activity of teleost type I interferon is conferred by a membrane-targeting C-terminal peptide

|
By Han Zhang, Ying Choon Wu, Xiaoyuan Zheng, PLOS Pathogens
| PLOS
Loading metrics Open Access Peer-reviewed Research Article Citation: Zhang H, Wu Y, Zheng X, Wang Z, Zhang C, Cao Z, et al. (2026) Noncanonical bactericidal activity of teleost type I interferon is conferred by a membrane-targeting C-terminal peptide. PLoS Pathog 22(7): e1014419. https://doi.org/10.1371/journal.ppat.1014419 Editor: Nuno M. S.
Open in Who Shared Issue with article?
|
By Qingyuan Xu, Linya Wang, Ning Liao, Mincui Zheng, Yunpeng Dai, Shaoyan Hu, Li Wang, Qun Hu, Xin Tian, Xiaohuan Wang, Yuanyuan Zhang, Pengli Huang, Ying Choon Wu, Wei Lin, Jia Fan, Ruidong Zhang, Yaguang Peng, Huyong Zheng, Diying Shen, Jiaole Yu, Peijing Qi
| Nature Verified
In recent years, the targeted therapy combining arsenic with all-trans retinoic acid (ATRA) has dramatically improved outcomes in pediatric acute promyelocytic leukemia (APL) [1, 2]. However, 5–10% of patients still experience relapse [3], which remains a major barrier to cure. Within this modern therapeutic framework, the risk factors for relapse in pediatric APL—particularly the role of arsenic pharmacokinetics—are not fully defined.
Open in Who Shared Issue with article?
See all 88 articles